Dr. Yelin has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Amgen.
Special Articles: Biologic Agents in the Treatment of Rheumatic Diseases-The First Decade
Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists†
Article first published online: 29 APR 2009
Copyright © 2009 by the American College of Rheumatology
Arthritis Care & Research
Volume 61, Issue 5, pages 593–599, 15 May 2009
How to Cite
Katz, P., Yelin, E., Patel, V., Huang, X.-Y. and Chiou, C.-F. (2009), Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists. Arthritis & Rheumatism, 61: 593–599. doi: 10.1002/art.24511
Because Drs. Katz and Yelin are Editors of Arthritis Care & Research, review of this article was handled by the Editor of Arthritis & Rheumatism.
- Issue published online: 29 APR 2009
- Article first published online: 29 APR 2009
- Manuscript Accepted: 3 MAR 2009
- Manuscript Received: 12 SEP 2008
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: AR-50015
To examine self-reported symptoms and functioning in a community-based sample of persons with rheumatoid arthritis who did and did not initiate treatment with biologic agents.
Data were from annual telephone interviews (1998–2003) with an observational cohort identified through community rheumatologists. Self-reported function and symptoms of subjects who initiated biologic therapy (etanercept or infliximab) and reported consistent use at 2 annual interviews (continuous use; n = 64) were compared at 1 year prior to initiation of therapy (baseline), and years 1 and 2 of therapy to those with no biologic therapy (n = 183) and those who initiated biologic therapy but discontinued use (n = 42).
At baseline, subjects taking biologic agents reported significantly worse function and symptoms on all measures except fatigue and pain severity. After 2 years, significant differences in the Health Assessment Questionnaire scores remained, but there were no other significant differences between the nonuser group and the continuous use group. The discontinued use group exhibited significantly greater pain severity and more painful joints than nonusers. Improvements in the number of painful (33.4% versus 16.2%; P = 0.004), and swollen (38.4% versus 18.7%; P = 0.003) joints, and morning stiffness (27.3% versus 10.4%; P = 0.001) were more frequent in the continuous use group than in the nonuser group.
Results suggest that biologic treatment was initiated based on severe disease. Over ∼17 months of treatment, differences in some but not all symptoms between the continuous use group and the nonuser group narrowed to statistical nonsignificance.